NCT01525082 2024-02-06Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsStanford UniversityPhase 2 Completed20 enrolled 15 charts
NCT02831179 2017-09-28Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorVanderbilt-Ingram Cancer CenterPhase 1 Withdrawn